Vol 101, No 5 (2025)
- Year: 2025
- Published: 13.12.2025
- Articles: 9
- URL: https://vestnikdv.ru/jour/issue/view/118
- DOI: https://doi.org/10.25208/vdv.1015
Full Issue
HEALTH ORGANIZATION
Key indicators of resources and performance of medical organizations providing medical care in the field of dermatovenereology. Incidence of sexually transmitted infections, diseases of the skin and subcutaneous tissue in the Russian Federation in 2022–2024
Abstract
Analysis of main indicators of dermatovenereology service of the Russian Federation in 2022–2024 is presented in the paper, including the following: the number of specialized medical organizations and departments, provision of the population of the Russian Federation with dermatovenereologists, dermatovenereologic beds, performance bed rates of dermatovenereologic 24-hour and day hospitals. The incidence of sexually transmitted infections in the entire population of the Russian Federation is presented: the incidence of various forms of syphilis, gonococcal infection, trichomoniasis, chlamydial infection, anogenital herpes viral infection and anogenital venereal warts; the contribution of foreign citizens to syphilis incidence is estimated. The prevalence and incidence rates of skin and subcutaneous tissue diseases by class, atopic dermatitis, psoriasis, contact dermatitis, other dermatitis (eczema), localized scleroderma, discoid lupus erythematosus. for the entire population of the Russian Federation are described.
9-21
REVIEWS
Epidermolysis bullosa simplex: genotype-phenotype correlations
Abstract
Epidermolysis bullosa simplex (EBS) includes a group of diseases characterized by varying severity, possible damage to visceral organs, and various outcomes ranging from complete regression of the rash to death. The initial clinical manifestations of EBS do not allow for predicting further course of the disease, however clinical and genetic correlations may be used for this purpose. We analyzed the literature from the PubMed and RSCI databases to characterize the clinical and genetic correlations in EBS. The analysis revealed that the most severe course of skin lesions in patients with EBS is associated with mutations in the KRT5 and KRT14 genes which alter the HIP (helix initiation peptide) and HTP (helix termination peptide) motifs in the corresponding proteins as well as the helical regions of keratins 5 and 14. The study also identified factors that can reduce reliability of predicting the course of EBS using clinical and genetic correlations. These include the degree of difference in the physical and chemical properties of the mutant and wild-type amino acids in case of missense mutations as well as the possible influence of other gene variants that may contribute to the clinical presentation of the disease. Detection of PLEC1 gene mutations suggests the possibility of developing muscular dystrophy, KLHL24 cardiomyopathy, CD151 nephropathy and deafness over the course of an EBS patient’s life. Thus, clinical and genetic correlations have been established that can be used to predict the course of EBS, and limitations for their application have been determined.
22-44
Systematization of the two-decade world experience using tacrolimus ointment off-label. Fundamental information on the product, its use in vitiligo and fibrosing connective tissue diseases
Abstract
Developed in the 1990s and introduced into clinical practice in the first decade of the 21st century, tacrolimus ointment (known worldwide under the trade name Protopic®) became the first and most potent member of the class of topical calcineurin inhibitors (TCIs) and the first alternative to topical glucocorticosteroids (TGCs) in terms of its anti-inflammatory activity in half a century. Its unique mechanism of action (selective T-cell immunosuppressant) and the absence of side effects typical of TGCs have made it a valuable tool in the therapeutic arsenal of dermatologists. Today, tacrolimus ointment is included in all possible international and national clinical guidelines for the treatment of atopic dermatitis, which is the only registered indication, and has the highest level of evidence (1A). Unfortunately, for a number of reasons, mostly commercial in nature, the manufacturer did not invest in a clinical trial program that would have allowed the registration of tacrolimus ointment for other indications. However, it is clear that the T-cell immune response plays a crucial role in pathogenesis of a wide range of dermatoses, and the pharmacodynamics of tacrolimus are well-suited for their treatment. In this regard, over the past two decades, hundreds of clinical studies have been conducted by independent investigators including well-designed double-blind randomized studies that have provided the evidence base for including tacrolimus ointment in the clinical guidelines for a wide range of off-label indications. The purpose of this review is to systematize the aforementioned global experience in order to raise awareness of clinicians and make more rational practical use of the valuable clinical tool, that is tacrolimus ointment. The first part of this review (the second part will be published later) provides general information on tacrolimus ointment including the history of its development, pharmacological characteristics and clinical applications as well as addressing off-label drug use. The evidence base for the use of tacrolimus ointment in the treatment of vitiligo and fibrosing connective tissue diseases will be analyzed.
45-57
ORIGINAL STUDIES
Experience with isotretinoin-lidose acne therapy
Abstract
Background. According to the World Health Organization, about 85 % of the global population suffers from acne. Isotretinoin, showing high clinical efficacy, is widely used for the treatment of moderate forms of this disease. This article presents an analysis of the clinical experience with isotretinoin in patients with moderate acne. The use of Lidose innovative patented technology allows for a 20% reduction in the daily dose of the active ingredient without compromising the clinical efficacy of the product which can improve its tolerability and enhance patient compliance.
Aim. To evaluate the clinical efficacy of isotretinoin, developed using Lidose technology, at doses of 8 mg and 16 mg.
Methods. This study analyzed data from 915 patients who received an innovative form of isotretinoin developed using Lidose technology over the past 5 years. All patients were treated for moderate to severe acne. The product dose was 0.4–0.8 mg/kg body weight per day.
Results. Isotretinoin therapy showed high efficacy in the treatment of moderate to severe acne. Clinical remission defined as complete or almost complete resolution of skin rashes (IGA score of 0 or 1) was achieved in 872 patients (95.3%). A significant improvement in skin condition, characterized by reduction in acne severity by ≥ 2 points on the Investigator’s Global Assessment (IGA) scale, was observed in 700 patients (76.4%) after 3 months of therapy. Generally, the number of inflammatory sites (papules, pustules, and nodules) decreased by 89.2% by the end of the treatment course (p < 0.001).
Conclusion. The innovative dosage form of isotretinoin developed using Lidose technology is characterized by high efficacy and good tolerability. This allows to consider it as a full-fledged alternative to the original isotretinoin with optimized bioavailability which ensures therapeutic effect at reduced dosages.
58-64
Retrospective study of the clinical and epidemiological features of syphilis in patients with HIV infection in Saint Petersburg
Abstract
Background. In the recent years, cases of syphilis and HIV infection have become more common in dermatovenerological practice due to increasing prevalence of HIV infection in the population.
Aim. Assessment of the clinical and epidemiological features of syphilis against HIV infection in modern settings.
Methods. A post-hoc analysis was conducted on the medical histories of 280 HIV-positive patients with syphilis who were under dispensary supervision at the St. Petersburg Center for AIDS and Infectious Diseases in 2018–2023.
Results. The group of patients with a combined syphilis and HIV infection was characterized by predominance of males (91.8%), young age (Q2 = 34 years), stage 4 HIV infection (66.5%), promiscuous behavior (60.8%), and homosexual contacts (67.7%). The most common clinical form of syphilis was neurosyphilis (37.2% of cases), and 61.5 % of patients had asymptomatic meningitis. The differences in the clinical presentation of syphilis in HIV-infected patients compared to the “classical” presentation were due to both immunodeficiency and behavioral characteristics of the patients which explains common occurrence of extragenital (21.1%) and multiple (63.2%) chancres as well as high frequency of recurring infection (29.0%). In 54.6% of patients, syphilis occurred without skin or mucosal lesions, making diagnosis difficult.
Conclusion. Despite the steady improvement in our knowledge of syphilis and HIV, managing patients with a combination of these infections remains a challenging task for a venereologist. Common latent course of syphilis and high prevalence of recurring infections underline the importance of regular serological screening for syphilis in HIV-infected patients. High incidence of neurosyphilis in the study group combined with its asymptomatic course requires examination of cerebrospinal fluid in all patients with coinfection.
65-77
GUIDELINES FOR PRACTITIONERS
Dermoscopy in the diagnosis of cutaneous B-cell lymphomas
Abstract
The diagnosis of cutaneous B-cell lymphomas is a challenging clinical task due to nonspecific nature of the skin manifestations in this disease. Since 2015, dermatoscopy has been used as an additional research method for the diagnosis of cutaneous B-cell lymphomas. Dermatoscopy is an inexpensive, non-invasive, and painless diagnostic method that allows to quickly obtain additional information about the disease. Currently known dermatoscopic signs, taking into account clinical and history data, may suggest a diagnosis of cutaneous B-cell lymphoma. The article clearly demonstrates the possibilities of dermatoscopy in the diagnosis of cutaneous B-cell lymphomas. However, dermatoscopy cannot replace the pathomorphological and immunohistochemical study of a skin biopsy which is the “golden standard” required for the diagnosis of cutaneous B-cell lymphoma. In some cases, a molecular genetic screening is performed to determine B-cell clonality in primary marginal zone cutaneous lymphomas with a pronounced T-cell component.
78-92
Miescher granulomatous cheilitis as a monosymptomatic variant of Melkersson–Rosenthal syndrome
Abstract
Granulomatous cheilitis is a chronic swelling of one or both lips that is caused by granulomatous inflammation. This is a rare inflammatory disease that belongs to the monosymptomatic form of Melkersson–Rosenthal syndrome. To date, the etiology of this disease remains unknown, and its treatment is challenging. The article discusses a case report of a monosymptomatic variant of recurrent orofacial edema, describes the features of the observed case and efficacy of intradermal application of glucocorticosteroids and fractional photothermolysis, and provides data on the differential diagnosis of the disease. This case highlights the importance of thorough examination in the diagnosis process as the clinical presentation can be similar to many other granulomatous conditions.
93-99
CLINICAL CASE REPORTS
Norwegian scabies in a patient with Down syndrome
Abstract
The article describes a case report of Norwegian scabies in a 36-year-old patient with Down syndrome who lived in a psychiatric nursing home. The diagnosis was made by a dermatovenerologist during an annual periodic medical examination in 2009. There was a total (generalized) skin lesion in the form of erythroderma and massive scales on the forehead and scalp as well as on the distal parts of the upper and lower extremities. On the skin of the trunk and extremities, there were widespread papular elements, erosions, purulent and hemorrhagic crusts, and lichenification. Attention should be paid to the fact that typical scabies was detected a year earlier, which can often occur as in-hospital outbreaks in medical and preventive institutions of this type. The recurrence of the disease could have been caused by inadequate control of the therapy by the patient himself and those around him — other patients in the nursing institution — as well as by poor hygiene habits and specific characteristics of the immune defense of the skin in patients with Down syndrome (such as T- and B-cell lymphopenia, decrease in the specific antibody response to immunization, defects in neutrophil chemotaxis, excessive free radical oxidation of cell membrane lipids, genetically determined by trisomy 21).
100-106
Late сardiovascular syphilis
Abstract
Since 1998, there has been an annual decrease in the incidence of syphilis in the Russian Federation; however, in 2021 and 2022, the incidence increased, compared to 2020, by 38 and 30%, respectively. In addition, for the first time in many years, the incidence of late syphilis (8.0 cases per 100,000 population) exceeded the incidence of early forms (7.2 cases per 100,000 population). The article presents a case report of late cardiovascular syphilis in a patient who had previously received treatment for the disease. The diagnosis of late cardiovascular syphilis was based on the patient’s medical history, clinical examination, serological blood tests and instrumental diagnostic methods, including transesophageal echocardiography and multispiral computed tomography, i.e., panarthrography of the thoracic and abdominal aorta. The patient has aortic, mitral, and tricuspid valve insufficiency, dilation of the ascending aorta and aortic arch, aneurysm of the descending thoracic aorta, dilation of the brachiocephalic trunk, right common carotid artery, and right subclavian artery, coronary heart disease, angina pectoris, paroxysmal atrial fibrillation, and cardiomegaly. The patient received specific treatment for late cardiovascular syphilis as well as surgical treatment for aortic valve disease and descending thoracic aortic aneurysm.
107-114






